These novel agents have demonstrated encouraging results in both preclinical models and early-phase clinical trials, leveraging the selective expression of DLL3 in SCLC to enhance therapeutic specificity and efficacy (25, 26). Here, DLL3 is linked to small cell lung carcinoma.